Evaluation of the efficacy and safety of anti-PD-1 and anti-PD-L1 antibody in the treatment of non-small cell lung cancer (NSCLC): a meta-analysis

BACKGROUND: Currently, blockade of the programmed cell death 1 (PD-1)/PD-1 ligand 1 (PD-L1) signaling pathway has been proved one of the most promising immunotherapeutic strategies against cancer. Several antibodies have been developed to either block the PD-1 or its ligand PD-L1 are under developme...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Thorac Dis
Main Authors: Jia, Minghan, Feng, Weijiao, Kang, Shiyang, Zhang, Yaxiong, Shen, Jianfei, He, Jiaxi, Jiang, Long, Wang, Wei, Guo, Zhihua, Peng, Guilin, Chen, Gang, He, Jianxing, Liang, Wenhua
Formato: Artigo
Idioma:Inglês
Publicado: AME Publishing Company 2015
Assuntos:
Original Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4387409/
https://ncbi.nlm.nih.gov/pubmed/25922725
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2072-1439.2015.02.06
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares